drugset / Trial / NCT01212276
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective, and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.
Timeline
- Start
- 2010-12
- Primary completion
- 2012-06
- Completion
- 2012-09
Outcome
Outcome not reported
Stopped: “Sponsor terminated protocol”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MORAb-028 | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | MORAb-028 | Monoclonal antibody | 0.2 mg/kg | Intravenous |
| Subject | MORAb-028 | Monoclonal antibody | 0.5 mg/kg | Intravenous |
| Subject | MORAb-028 | Monoclonal antibody | 1 mg/kg | Intravenous |